We are live on ! Find out more
EPRS

EPIRUS BIOPHARMACEUTICALS INC COM
EPRS

Delisted

EPRS was delisted on the 3rd of August, 2016.

Back to rankings

45 hedge funds and large institutions have $41.3M invested in EPIRUS BIOPHARMACEUTICALS INC COM in 2015 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 15 increasing their positions, 7 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

114% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 7

67% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 6

10% more funds holding

Funds holding: 41 → 45 (+4)

36% less capital invested

Capital invested by funds: $64.9M → $41.3M (-$23.6M)

99% less call options, than puts

Call options by funds: $3K | Put options by funds: $388K

Holders
45
Holders Change
+4
Holders Change %
+9.76%
% of All Funds
1.18%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
15
Reduced
7
Closed
6
Calls
$3K
Puts
$388K
Net Calls
-$385K
Net Calls Change
+$109K

Top Buyers

1
BC
Broadfin Capital
New York
+$2.7M
2
HCMT
Highland Capital Management (Texas)
Texas
+$1.98M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$1.13M
4
SIM
Spark Investment Management
New York
+$423K
5
BIT
BlackRock Institutional Trust
California
+$318K

Top Sellers

1
CCM
Consonance Capital Management
New York
-$10.3M
2
B
Bailard
California
-$1.56M
3
TC
TFS Capital
Pennsylvania
-$355K
4
NI
Numeric Investors
Massachusetts
-$254K
5
JCG
JHL Capital Group
Illinois
-$243K
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$49K +$19.6K +4,342 +37%
Citadel Advisors
27
Citadel Advisors
Florida
$45K +$65.5K +14,535 New
SCM
28
Sterling Capital Management
North Carolina
$43K +$62.8K +13,924 New
WS
29
Wedbush Securities
California
$41K – – –
Group One Trading
30
Group One Trading
Illinois
$41K +$39.8K +8,832 +204%
M&T Bank
31
M&T Bank
New York
$41K +$59.6K +13,211 New
AAP
32
Ardsley Advisory Partners
Connecticut
$31K -$22.5K -5,000 -33%
A
33
Abingworth
United Kingdom
$24K – – –
TRCT
34
Tower Research Capital (TRC)
New York
$10K -$3.99K -886 -21%
BJ
35
BlackRock Japan
Japan
$10K +$14.7K +3,262 New
BIM
36
BlackRock Investment Management
Delaware
$9K +$933 +207 +7%
UBS Group
37
UBS Group
Switzerland
$5K +$7.74K +1,717 +21,463%
CG
38
Cutler Group
California
$2K +$3.83K +850 New
Creative Planning
39
Creative Planning
Kansas
$1K – – –
Wells Fargo
40
Wells Fargo
California
$1K – – –
WA
41
WFG Advisors
Texas
$1K – – –
IA
42
IFP Advisors
Florida
$1K +$2.15K +476 New
Manulife (Manufacturers Life Insurance)
43
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$4 – – –
CCM
44
Consonance Capital Management
New York
– -$10.3M -2,324,669 Closed
TC
45
TFS Capital
Pennsylvania
– -$355K -80,294 Closed
NI
46
Numeric Investors
Massachusetts
– -$254K -57,408 Closed
JCG
47
JHL Capital Group
Illinois
– -$243K -55,000 Closed
ACM
48
Asymmetry Capital Management
California
– -$189K -42,787 Closed
Morgan Stanley
49
Morgan Stanley
New York
– -$6.76K -1,500 -91%
Citigroup
50
Citigroup
New York
– +$379 +84 New
1
2

EPRS Hedge Fund Activity: Q4 2015 in Review

45 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) for Q4 2015, worth a combined $41.3M — down 36% from $64.9M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new EPRS positions and 6 closed out — a net gain of 4 holders — while 15 added to existing stakes and 7 trimmed.

The largest buyer was Broadfin Capital, adding an estimated $2.7M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $10.3M sold.

  • 45 institutional investors held EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) as of Q4 2015, up from 41 in Q3 2015.
  • Funds reported $41.3M of EPIRUS BIOPHARMACEUTICALS INC COM stock for Q4 2015, down 36% quarter-over-quarter.
  • 10 funds opened new EPIRUS BIOPHARMACEUTICALS INC COM positions in Q4 2015 and 6 closed out, a net change of +4 holders.
  • The largest EPIRUS BIOPHARMACEUTICALS INC COM buyer in Q4 2015 was Broadfin Capital, an estimated $2.7M added.
  • The largest EPIRUS BIOPHARMACEUTICALS INC COM seller in Q4 2015 was Consonance Capital Management, an estimated $10.3M sold.

Based on aggregated 13F filings for Q4 2015.